Pricing Log in Create free account
Friday 6 November 2026 Export LKFT’s income statement to Excel — free account

Lakefront Biotherapeutics - Sponsored ADR

LKFT Healthcare Biotechnology

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.

Revenue
−95.4%
EPS
+198.9%
Free cash flow
+18.2%

Quarter to June 2026, against a year earlier

33.37 0.19 −0.57%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−15.3×
Dividend yield
—
F-score
6/9
Altman Z
8.43
Beneish M
0.34
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Lakefront Biotherapeutics - Sponsored ADR (LKFT) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Lakefront Biotherapeutics - Sponsored ADR (LKFT) trades at a EV/Sales of −1.3×. Over the past ten years it has ranged from −6.1× (May 2026) to 47.6× (January 2018); the current reading is higher than 47% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 −3.2× —
FY2024 −3.4× —
FY2023 −2.4× —
FY2022 −2.6× —
FY2021 −3.4× —
FY2020 0.9× (82.61%)
FY2019 5.4× (37.23%)
FY2018 8.7× (74.40%)
FY2017 33.9× 15.42%
FY2016 29.4× 7.33%

Quarterly newest first

Period EV/Sales Change
Mar 2026 −5.3× —
Mar 2025 −4.2× —
Mar 2024 −3.2× —
Sep 2023 −3.2× —
28 more quarters

Against its own ten years

Low −6.1× High 47.6×
Ten-year median 0.0×
Current reading's percentile 47

EV/Sales against peers

Company EV/Sales
LKFT Lakefront Biotherapeutics - Sponsored ADR −1.3×
VERA Vera Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
AUPH Aurinia Pharmaceuticals Inc compare 5.3×
VCEL Vericel Corporation compare 7.6×
SEPN Septerna, Inc. compare 18.1×
PVLA Palvella Therapeutics, Inc. compare 48.1×
ZYME Zymeworks Inc. compare 49.5×
IMNM Immunome, Inc. compare 121×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LKFT